Javascript must be enabled to continue!
TYPE‐I AND TYPE‐III HTLV ANTIBODIES IN HOSPITALIZED AND OUT‐PATIENT ZAIRIANS
View through CrossRef
Sera from 182 Zairians (99 females and 83 males), aged 5 to 71 years, including maternity and child care consultants, out‐patients suffering from minor injuries and patients hospitalized for tuberculosis, malaria or trauma, were analyzed for specific antibodies to HTLV‐I and HTLV‐III. Following pre‐screening by the ELISA technique, reactive sera were further analyzed for specificity to HTLV‐I or HTLV‐III antigens by competition and/or Western blotting experiments. African sera, possibly because they have higher immunoglobulin levels than US and European sera, are highly reactive in ELISA systems and confirmatory assays are essential to rule out false‐positive results. Confirmed antibody prevalence for HTLV‐I was 13.2% (II females and 13 males) and increased with age, suggesting continuous exposure to the virus throughout life. Confirmed antibody prevalence for HTLV‐III was 6.0% (8 females and 3 males) and showed a peak age range between 21 and 40 years, suggesting heterosexual transmission. Individuals positive for HTLV‐1 antibodies were not the same as individuals positive for HTLV‐ III antibodies, suggesting that infection with one virus did not increase susceptibility to infection by the other virus. Further investigations of the epidemiology and of the immunovirology of HTLV‐III in Zaire, in relation to acquired immuno‐deficiency syndrome (AIDS)‐associated pathologies, should enlighten the question of the significant percentage of HTLV‐III‐infected individuals who do not manifest symptoms of AIDS.
Title: TYPE‐I AND TYPE‐III HTLV ANTIBODIES IN HOSPITALIZED AND OUT‐PATIENT ZAIRIANS
Description:
Sera from 182 Zairians (99 females and 83 males), aged 5 to 71 years, including maternity and child care consultants, out‐patients suffering from minor injuries and patients hospitalized for tuberculosis, malaria or trauma, were analyzed for specific antibodies to HTLV‐I and HTLV‐III.
Following pre‐screening by the ELISA technique, reactive sera were further analyzed for specificity to HTLV‐I or HTLV‐III antigens by competition and/or Western blotting experiments.
African sera, possibly because they have higher immunoglobulin levels than US and European sera, are highly reactive in ELISA systems and confirmatory assays are essential to rule out false‐positive results.
Confirmed antibody prevalence for HTLV‐I was 13.
2% (II females and 13 males) and increased with age, suggesting continuous exposure to the virus throughout life.
Confirmed antibody prevalence for HTLV‐III was 6.
0% (8 females and 3 males) and showed a peak age range between 21 and 40 years, suggesting heterosexual transmission.
Individuals positive for HTLV‐1 antibodies were not the same as individuals positive for HTLV‐ III antibodies, suggesting that infection with one virus did not increase susceptibility to infection by the other virus.
Further investigations of the epidemiology and of the immunovirology of HTLV‐III in Zaire, in relation to acquired immuno‐deficiency syndrome (AIDS)‐associated pathologies, should enlighten the question of the significant percentage of HTLV‐III‐infected individuals who do not manifest symptoms of AIDS.
Related Results
Hematopoietic Stem Cell Infected with HTLV-1 Functions As a Viral Reservoir In Vivo
Hematopoietic Stem Cell Infected with HTLV-1 Functions As a Viral Reservoir In Vivo
Abstract
Human T-cell leukemia virus type 1 (HTLV-1) is a causative agent of a malignant disease of peripheral CD4+ T cells called adult T-cell leuke...
Rational Development of Serologic Assays for Anti-HTLV Antibodies.
Rational Development of Serologic Assays for Anti-HTLV Antibodies.
Abstract
Both HIV and HTLV virions are comprised mainly of gag proteins (p24 and p19 for HTLV) (Table 1); while both virions lack their primary RNA transcriptional r...
Hospital admissions in individuals with HTLV-1 infection in Spain
Hospital admissions in individuals with HTLV-1 infection in Spain
Objective:
To examine the clinical burden and disease spectrum, as well as time trends for human T-cell leukemia virus type 1 (HTLV-1) and HTLV type 2 (HTLV-2) hospital...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Detection of antibodies to human T‐lymphotropic virus type 1 (HTLV‐1)
Detection of antibodies to human T‐lymphotropic virus type 1 (HTLV‐1)
Sera from 39,898 blood donors were tested for HTLV‐1 antibodies using two enzyme immunoassays (EIA). Sera testing initially reactive (IR) were retested in duplicate by both EIAs. S...
HTLV infection in persons with sexually transmitted diseases in Spain
HTLV infection in persons with sexually transmitted diseases in Spain
BackgroundHTLV-1 infection is a neglected disease, despite estimates of 10 million people infected worldwide and producing life-threatening illnesses in 10% of carriers. Sexual tra...
Transcriptional and Epigenetic Regulatory Mechanisms Affecting HTLV-1 Provirus
Transcriptional and Epigenetic Regulatory Mechanisms Affecting HTLV-1 Provirus
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus associated with human diseases, such as adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/Tropic spastic para...
Apoptosis in labial salivary glands from Sjögren's syndrome (SS) patients: comparison with human T lymphotropic virus-I (HTLV-I)-seronegative and -seropositive SS patients
Apoptosis in labial salivary glands from Sjögren's syndrome (SS) patients: comparison with human T lymphotropic virus-I (HTLV-I)-seronegative and -seropositive SS patients
SUMMARYApoptosis is a type of cell death that occurs during morphogenesis and development of the immune system. One of the mechanisms is mediated through the Fas and Fas ligand (Fa...

